Enoxaparin for thromboembolism prophylaxis in spinal injury: Preliminary report on experience with 105 patients

Stacy Harris, David Chen, David Green*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Venous thromboembolism continues to be a major cause of morbidity and mortality in patients with spinal injury (SI). Recently, we reported on the effectiveness and safety of a low molecular weight heparin (LMWH), tinzaparin, in preventing deep vein thrombosis in motor-complete SI patients. Recently, another LMWH, enoxaparin, was approved by the United States Food and Drug Administration for prevention of thromboembolism in hip and knee replacement surgery. Since its approval, we have used 30 mg of enoxaparin subcutaneously every 12 h as routine prophylaxis in all hospitalized SI patients. In this retrospective study, we present an analysis of safety and efficacy of the first six months experience, during which 105 patients received the drug. No patient developed clinical evidence of thromboembolism, and none of the 60 venous ultrasound examinations showed a deep vein thrombus. Eleven patients had evidence of hemorrhage, but the LMWH was considered to have contributed to the bleeding in only three. This additional experience with enoxaparin reinforces our previous conclusion that LMWHs are safe and effective thromboprophylactic agents in SI patients.

Original languageEnglish (US)
Pages (from-to)326-327
Number of pages2
JournalAmerican Journal of Physical Medicine and Rehabilitation
Issue number5
StatePublished - Jan 1 1996


  • Low Molecular Weight Heparin
  • Spinal Injury
  • Thromboembolism

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation


Dive into the research topics of 'Enoxaparin for thromboembolism prophylaxis in spinal injury: Preliminary report on experience with 105 patients'. Together they form a unique fingerprint.

Cite this